FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138405392> ?p ?o ?g. }

• W2138405392 endingPage "3074" @default.
• W2138405392 startingPage "3065" @default.
• W2138405392 abstract "The type I insulin-like growth factor receptor (IGF-IR) and its ligands have been shown to play a critical role in prostate carcinoma development, growth, and metastasis. Targeting the IGF-IR may be a potential treatment for prostate cancer. A fully human monoclonal antibody, A12, specific to IGF-IR, has shown potent antitumor effects in breast, colon, and pancreatic cancers in vitro and in vivo. In this study, we tested the in vivo effects of A12 on androgen-dependent and androgen-independent prostate tumor growth.Androgen-dependent LuCaP 35 and androgen-independent LuCaP 35V prostate tumors were implanted s.c. into intact and castrated severe combined immunodeficient mice, respectively. When tumor volume reached about 150 to 200 mm(3), A12 was injected at 40 mg/kg body weight thrice a week for up to 5 weeks.We find that A12 significantly inhibits growth of androgen-dependent LuCaP 35 and androgen-independent LuCaP 35V prostate xenografts, however, by different mechanisms. In LuCaP 35 xenografts, A12 treatment induces tumor cell apoptosis or G(1) cycle arrest. In LuCaP 35V xenografts, A12 treatment induces tumor cell G(2)-M cycle arrest. Moreover, we find that blocking the function of IGF-IR down-regulates androgen-regulated gene expression in androgen-independent LuCaP 35V tumor cells.Our findings suggest that A12 is a therapeutic candidate for both androgen-dependent and androgen-independent prostate cancer. Our findings also suggest an IGF-IR-dependent activity of the androgen receptor in androgen-independent prostate cancer cells." @default.
• W2138405392 created "2016-06-24" @default.
• W2138405392 creator A5000715807 @default.
• W2138405392 creator A5016557983 @default.
• W2138405392 creator A5056550116 @default.
• W2138405392 creator A5057037633 @default.
• W2138405392 creator A5071161054 @default.
• W2138405392 creator A5071983100 @default.
• W2138405392 creator A5076095831 @default.
• W2138405392 date "2005-04-15" @default.
• W2138405392 modified "2023-09-26" @default.
• W2138405392 title "<i>In vivo</i> Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate Tumors" @default.
• W2138405392 cites W1488956616 @default.
• W2138405392 cites W1969898679 @default.
• W2138405392 cites W1972485897 @default.
• W2138405392 cites W1976128207 @default.
• W2138405392 cites W1981354181 @default.
• W2138405392 cites W2001981755 @default.
• W2138405392 cites W2005873549 @default.
• W2138405392 cites W2006754781 @default.
• W2138405392 cites W2009876678 @default.
• W2138405392 cites W2014303129 @default.
• W2138405392 cites W2015524046 @default.
• W2138405392 cites W2017757468 @default.
• W2138405392 cites W2018697055 @default.
• W2138405392 cites W2026790929 @default.
• W2138405392 cites W2029347223 @default.
• W2138405392 cites W2029863620 @default.
• W2138405392 cites W2033032904 @default.
• W2138405392 cites W2041750137 @default.
• W2138405392 cites W2043529958 @default.
• W2138405392 cites W2051984702 @default.
• W2138405392 cites W2068063264 @default.
• W2138405392 cites W2071347266 @default.
• W2138405392 cites W207447872 @default.
• W2138405392 cites W2082025128 @default.
• W2138405392 cites W2083227753 @default.
• W2138405392 cites W2089267976 @default.
• W2138405392 cites W2111843196 @default.
• W2138405392 cites W2120877279 @default.
• W2138405392 cites W2126071672 @default.
• W2138405392 cites W2130284279 @default.
• W2138405392 cites W2150261924 @default.
• W2138405392 cites W2164787718 @default.
• W2138405392 cites W2343091502 @default.
• W2138405392 cites W2400253897 @default.
• W2138405392 cites W4237186569 @default.
• W2138405392 cites W4241663333 @default.
• W2138405392 cites W6853850 @default.
• W2138405392 cites W203092201 @default.
• W2138405392 doi "https://doi.org/10.1158/1078-0432.ccr-04-1586" @default.
• W2138405392 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15837762" @default.
• W2138405392 hasPublicationYear "2005" @default.
• W2138405392 type Work @default.
• W2138405392 sameAs 2138405392 @default.
• W2138405392 citedByCount "163" @default.
• W2138405392 countsByYear W21384053922012 @default.
• W2138405392 countsByYear W21384053922013 @default.
• W2138405392 countsByYear W21384053922014 @default.
• W2138405392 countsByYear W21384053922015 @default.
• W2138405392 countsByYear W21384053922016 @default.
• W2138405392 countsByYear W21384053922017 @default.
• W2138405392 countsByYear W21384053922019 @default.
• W2138405392 countsByYear W21384053922020 @default.
• W2138405392 countsByYear W21384053922022 @default.
• W2138405392 countsByYear W21384053922023 @default.
• W2138405392 crossrefType "journal-article" @default.
• W2138405392 hasAuthorship W2138405392A5000715807 @default.
• W2138405392 hasAuthorship W2138405392A5016557983 @default.
• W2138405392 hasAuthorship W2138405392A5056550116 @default.
• W2138405392 hasAuthorship W2138405392A5057037633 @default.
• W2138405392 hasAuthorship W2138405392A5071161054 @default.
• W2138405392 hasAuthorship W2138405392A5071983100 @default.
• W2138405392 hasAuthorship W2138405392A5076095831 @default.
• W2138405392 hasConcept C121608353 @default.
• W2138405392 hasConcept C126322002 @default.
• W2138405392 hasConcept C150903083 @default.
• W2138405392 hasConcept C207001950 @default.
• W2138405392 hasConcept C2776235491 @default.
• W2138405392 hasConcept C2777911890 @default.
• W2138405392 hasConcept C2779013556 @default.
• W2138405392 hasConcept C2780192828 @default.
• W2138405392 hasConcept C502942594 @default.
• W2138405392 hasConcept C61367390 @default.
• W2138405392 hasConcept C71315377 @default.
• W2138405392 hasConcept C71924100 @default.
• W2138405392 hasConcept C86803240 @default.
• W2138405392 hasConceptScore W2138405392C121608353 @default.
• W2138405392 hasConceptScore W2138405392C126322002 @default.
• W2138405392 hasConceptScore W2138405392C150903083 @default.
• W2138405392 hasConceptScore W2138405392C207001950 @default.
• W2138405392 hasConceptScore W2138405392C2776235491 @default.
• W2138405392 hasConceptScore W2138405392C2777911890 @default.
• W2138405392 hasConceptScore W2138405392C2779013556 @default.
• W2138405392 hasConceptScore W2138405392C2780192828 @default.
• W2138405392 hasConceptScore W2138405392C502942594 @default.
• W2138405392 hasConceptScore W2138405392C61367390 @default.
• W2138405392 hasConceptScore W2138405392C71315377 @default.

• next